Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;483(4):509-516.
doi: 10.1007/s00428-023-03629-z. Epub 2023 Aug 23.

Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors

Adam Šafanda  1 , Michaela Kendall Bártů  1 , Romana Michálková  1 , Ivana Stružinská  1 , Jana Drozenová  2 , Pavel Fabián  3 , Jitka Hausnerová  4 , Jan Laco  5 , Radoslav Matěj  1   2   6 , Petr Škapa  7 , Marián Švajdler  8 , Zuzana Špůrková  9 , Gábor Méhes  10 , Pavel Dundr  1 , Kristýna Němejcová  11
Affiliations

Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors

Adam Šafanda et al. Virchows Arch. 2023 Oct.

Abstract

Preferentially expressed antigen of melanoma (PRAME) is a cancer/testis antigen selectively expressed in somatic tissues and various solid malignant tumors and is associated with poor prognostic outcome. Our research aimed to comprehensively compare its expression in a large cohort of tubo-ovarian epithelial tumors and examine its correlation with our clinico-pathologic data, as well as to assess its potential use in diagnostics and therapy.We examined 485 cases of epithelial tubo-ovarian tumors including 107 clear cell carcinomas (CCC), 52 endometroid carcinomas (EC), 103 high grade serous carcinomas (HGSC), 119 low grade serous carcinomas (LGSC)/micropapillary variant of serous borderline tumors (mSBT), and 104 cases of mucinous carcinomas (MC)/mucinous borderline tumors (MBT). The immunohistochemical analysis was performed using TMAs.The highest levels of expression were seen in EC (60%), HGSC (62%), and CCC (56%), while expression in LGSC/mSBT (4%) and MC/MBT (2%) was rare. The clinico-pathologic correlations and survival analysis showed no prognostic significance.The results of our study showed that PRAME is neither prognostic nor a suitable ancillary marker in the differential diagnosis of tubo-ovarian epithelial tumors. Nevertheless, knowledge about the PRAME expression may be important concerning its potential predictive significance, because targeting PRAME as a potential therapeutic option is currently under investigation.

Keywords: Cancer; Immunohistochemistry; Ovarian tumors; PRAME.

PubMed Disclaimer

References

    1. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22–32. https://doi.org/10.1034/j.1600-065x.2002.18803.x - DOI - PubMed
    1. Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6(2):199–208. https://doi.org/10.1016/s1074-7613(00)80426-4 - DOI - PubMed
    1. Caballero OL, Chen Y-T (2009) Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci 100:2014–2021. https://doi.org/10.1111/j.1349-7006.2009.01303.x - DOI - PubMed
    1. Yao J, Caballero OL, Yung WK, Weinstein JN, Riggins GJ, Strausberg RL, Zhao Q (2014) Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res 2(4):371–379. https://doi.org/10.1158/2326-6066.CIR-13-0088 - DOI - PubMed
    1. Li J, Yin J, Zhong J, Yang Z, Tang A, Li S (2020) Clinicopathological and Prognostic Significance of PRAME Overexpression in Human Cancer: A Meta-Analysis. Biomed Res Int 2020:8828579. https://doi.org/10.1155/2020/8828579 - DOI - PubMed - PMC

LinkOut - more resources